Yes, melatonin production decreases with age, but the decline is not linear, not universal, and smaller than most supplement marketing implies. The best-documented change is a drop in the nightly peak, beginning in early adulthood and steepening after roughly age 60. Total 24-hour output falls too, mainly because the pineal gland produces less at night rather than because the rhythm disappears. Daytime levels stay low at every age. The clinical consequence is narrower than the internet suggests: sleep timing and light exposure explain more age-related sleep change than melatonin loss does.

The synthesis chain and why it slows

Melatonin is made in the pineal gland from serotonin, which is built from tryptophan. The rate-limiting step is the enzyme that converts serotonin to melatonin, and that enzyme is switched on by norepinephrine released from sympathetic nerve endings at night. The pineal acts as a neuroendocrine transducer: it converts a light signal into a chemical one. Light detected by the retina, especially blue-enriched light, suppresses the signal. Darkness permits it.

Two age-related changes matter. First, the pineal gland accumulates calcium phosphate deposits, sometimes called acervuli or brain sand, and these deposits increase with age on imaging. Whether deposits directly displace melatonin-producing cells or are mostly a marker of gland aging is still debated. Second, the sympathetic input and the beta-adrenergic signaling downstream of it appear to weaken in older animals and humans. Less signal means less enzyme activity means a lower nightly peak.

A third mechanism sits upstream. With age, the lens yellows and the pupil narrows, so less light reaches the retina. That sounds like it should help older adults sleep by reducing suppression. In practice, the same optical changes reduce the bright-light signal the circadian clock needs to stay synchronized, which can shift timing earlier. The clock and the gland are separate problems. Melatonin decline is the gland; sleep timing is the clock.

The plain-language version: the factory gets smaller and its night-shift signal gets weaker, but it rarely shuts down.

How large is the decline, and when does it happen

The most-cited human evidence comes from cross-sectional studies measuring melatonin in blood or its urinary metabolite. The pattern across studies is consistent in direction but variable in size. Nightly peak concentrations in healthy older adults are commonly reported at roughly one-half to one-quarter of values in young adults, with wide individual overlap. Some older adults have peaks indistinguishable from young adults. Cross-sectional data cannot separate aging from cohort effects, and longitudinal data are scarce.

The shape of the decline matters more than the average. The fall appears modest through midlife and steeper after about 60. Pineal calcification visible on CT scans becomes common in later decades, though the correlation between calcification and melatonin output is imperfect. Melatonin also declines in people with Alzheimer's disease more than in cognitively normal peers of the same age, which flags neurodegeneration as a confounder rather than aging alone.

Interpret absolute numbers cautiously. Melatonin is measured in different matrices (plasma, saliva, urine metabolite), at different times relative to dim-light onset, with different assays. A "50 percent decline" from one study should not be treated as a universal conversion factor. The defensible claim is a substantial reduction in nocturnal amplitude with preserved daytime suppression.

Age band Typical nocturnal melatonin pattern Main caveat
Adolescence to 20s Highest peaks in most studies; timing often delayed Timing shifts can mimic low output
30s to 40s Peak begins to decline modestly Few longitudinal data
50s Intermediate values; wide overlap with younger adults Health status dominates
60s to 70s Lower peaks; steeper decline reported Lens and pupil changes alter light input
80s and beyond Lowest average peaks; some individuals retain robust rhythms Comorbidity and medications confound
Alzheimer's disease (any age) Lower peaks and disrupted rhythm beyond age norms Disease effect, not aging

What the decline does and does not cause

Melatonin is a timing signal, not a sleep switch. It feeds back on the suprachiasmatic nucleus and helps consolidate the circadian rhythm, and it acts on peripheral clocks throughout the body. A lower nightly peak may weaken that internal time cue, which can make sleep more fragmented and less consolidated. This is a plausible mechanism, not a proven dose-response relationship in free-living older adults.

The counterintuitive part: age-related sleep complaints track light exposure and circadian timing more closely than they track melatonin concentration. Older adults spend more time indoors, receive less daytime bright light, and often go to bed earlier relative to their internal clock. Those changes shrink the circadian amplitude and advance sleep timing. Melatonin decline is real, but it is one input among several, and correcting the others often changes sleep more than adding melatonin does.

A professional caveat worth stating plainly: the pineal output that matters most may be the duration and consistency of the nocturnal signal, not the peak height. An older adult with a modest but stable rhythm may sleep better than one with a higher but erratic peak.

Common misconceptions

The first misconception is that melatonin "runs out" and must be replaced. Production falls but does not stop in healthy aging, and the rhythm usually persists. The second is that lower melatonin proves a deficiency disease. No major body defines age-related melatonin decline as a deficiency state requiring treatment. The third is that supplements restore youthful pineal function. Exogenous melatonin raises circulating levels, but it does not rejuvenate the gland's synthetic capacity; it adds an external signal.

The fourth is that higher doses work better. Physiologic replacement aims to mimic a normal nighttime profile. Supraphysiologic doses produce high circulating levels but do not necessarily improve sleep, and they may shift timing unpredictably. The fifth is that melatonin is risk-free because it is sold without a prescription. In the United States, melatonin is regulated as a dietary supplement rather than a drug, so potency and purity vary across products.

Do not give melatonin to children without a clinician's guidance; dosing and long-term effects are not established for pediatric use. Stop melatonin and seek advice if you develop new daytime sleepiness, headaches, or vivid dreams that disrupt sleep. Treat any supplement as a possible drug interaction; melatonin can interact with anticoagulants, immunosuppressants, and some antidepressants. Do not use melatonin to self-treat chronic insomnia without addressing sleep timing, light exposure, and caffeine or alcohol use. If sleep problems include loud snoring, gasping, or restless legs, get evaluated before adding any sleep aid.

Practical steps that target the mechanism

The actionable levers act on the light-and-timing system that sets melatonin release. Morning bright light is the strongest anchor. Aim for outdoor light within an hour of waking for at least 20 to 30 minutes on most days; indoor lighting is far weaker than daylight even on overcast mornings. Evening dimness matters as much. Reduce bright overhead light and screen brightness in the two hours before bed.

Keep sleep and wake times consistent within roughly 30 minutes, including weekends. That stabilizes the clock that melatonin signals to. If you use melatonin, treat it as a timing tool rather than a sedative: a low dose taken in the evening before the intended sleep time is the conventional approach for shifting rhythm, but specific dosing is a clinical decision, not a self-directed protocol. Avoid alcohol as a sleep aid; it fragments the second half of the night.

Check medications with a pharmacist. Beta-blockers can suppress melatonin release, and several common drug classes affect sleep architecture. If you want to know your own pattern, a clinician can order salivary or plasma melatonin testing, but such testing is rarely necessary and results vary by lab.

Where the evidence stops

The causal chain is strongest at the biochemical level and weaker at the population level. Animal studies show clear age-related loss of pineal synthetic capacity. Human cross-sectional studies show lower nocturnal peaks in older adults. What is missing is long-term longitudinal data linking individual melatonin trajectories to individual sleep outcomes, and trials showing that restoring youthful melatonin levels improves healthspan.

Be equally skeptical of claims in both directions. "Melatonin drops 80 percent by age 60" is not a number any single authoritative source supports as a universal figure. "Melatonin decline is irrelevant" overstates the case; the rhythm does weaken with age and neurodegeneration. The honest position is that age-related melatonin decline is real, usually moderate, highly variable between people, and one factor among many in how sleep changes across the lifespan.

That framing also explains why supplement reviews and thin explainers converge on the same unsatisfying answer. The interesting science is not the number. It is the mechanism: a calcifying gland, a weakening sympathetic signal, a yellowing lens, and a clock that needs light to stay set. Address those, and the melatonin question becomes less urgent.